Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer
2024-519825-39-00Phase 2Authorised
- Sponsor
- Clínica Universidad de Navarra
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of oxaliplatin and capecitabine in colon cancer (2 arms), sponsored by Clínica Universidad de Navarra. Primary endpoint: 2-year disease-free survival. Planned start Jan 2025; status: authorised.
02
Drugs
oxaliplatincapecitabine
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2024-519825-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519825-39-00.